


**Cell Reports, Volume 39**

**Supplemental information**

**Functional properties of the spike glycoprotein  
of the emerging SARS-CoV-2 variant B.1.1.529**

**Qian Wang, Saumya Anang, Sho Iketani, Yicheng Guo, Lihong Liu, Phinikoula S. Katsamba, Lawrence Shapiro, David D. Ho, and Joseph G. Sodroski**



**Figure S1.** The infectivity of VSV vectors pseudotyped by the variant SARS-CoV-2 S glycoproteins on 293T cells transfected with the indicated amounts of an ACE2-expressing plasmid. Four independent experiments are shown and data are presented as the means and standard deviations derived from triplicate samples. **See also figure 2A, B.**







Figure S2. SDS-polyacrylamide gel of purified D614G and B.1.1.529 S2P spike trimers. See also figure 3B, figure 5A and figure 5C.



**Figure S3. Binding of sera from patients convalescing from COVID-19 (CP1-CP6) and Moderna vaccinee sera (V1-V6) to the SARS-CoV-2 D614G and B.1.1.529 S2P trimers (A) and RBD proteins (B).** The S2P trimers and RBD proteins were captured on ELISA plates. Serially diluted sera (starting from 1:100) were incubated with the plates and the bound antibodies were measured. Dashed lines show a level 3-fold above the background  $OD_{450}$  values. Data are presented as means  $\pm$  SEM. See also figure 5A and 5C.

**A****B**

**Figure S4. Neutralization of VSV pseudotypes by sera from patients convalescing from COVID-19 and vaccinees.** Neutralization curves are shown of sera from patients convalescing from COVID-19 (CP1-CP11) and Moderna vaccinee sera (V1-V6) against VSV particles pseudotyped by the variant SARS-CoV-2 S glycoproteins on Vero-E6 (**A**) and 293T-ACE2 (**B**) cells. Data are presented as means  $\pm$  SEM. See also figure 5B and 5D.